Clinical Trial of the Week: Treatment trial for patients diagnosed with certain recurrent gynecologic cancers

By Donna Loyle, communications specialist, LIMR

Researchers are conducting a randomized clinical trial to determine if the experimental drug cediranib maleate and the FDA-approved Lynparza™ (olaparib) may stop the growth of ovarian, fallopian tube and primary peritoneal tumor cells by blocking enzymes needed for cell growth. They are comparing the drug regimen to non-platinum standard chemotherapy.

This trial is for previously treated patients with recurrence of the above-noted cancers.

Eligible patients are those deemed platinum-resistant or -refractory. Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must either serous or endometrioid cancer based on local histopathological findings. Both endometrioid and serous histology should be high-grade for eligibility of non-mutation carriers.

Patients with clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma histologies are also eligible, provided the patient has a known deleterious germline BRCA1 or BRCA2 mutation. Other inclusion/exclusion criteria apply. Please see the website for additional information.

Study participants are grouped into three treatment arms:

  • standard non-platinum chemotherapy
  • cediranib maleate and olaparib
  • only cediranib maleate

Patients undergo follow-up care for up to five years.

Trial NRG GY005 is approved for Lankenau Medical Center and Paoli Hospital. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more information, visit

Posted in Uncategorized | Leave a comment

2020 United Way Campaign

Dear Colleagues,

We are thrilled to share that today kicks off our 2020 United Way campaign! Thank you to all who have donated previously to our campaigns and for your commitment to supporting the greater community in which we work and live. Main Line Health’s relationship with the United Way spans more than two decades and, because of your generosity, we have raised more than $3 million dollars for the Southeastern PA region. Our annual participation in the United Way campaign is yet another example of how we deliver human care to our neighbors.

As we launch our 2020 campaign today, we hope to raise even more. This year, we’ve set a goal of $150,000—and we are confident that we can meet (and even exceed) that goal with your help. Regardless of how much you are able to donate, every dollar goes directly to those in our communities who need and depend on our support. To make a donation to this year’s campaign—which will run through February 21—visit the United Way page on WellSpring or donate directly through PeopleSoft. You can also fill out the attached pledge form, and Payroll will enter your donation into PeopleSoft directly. You can mail your paper pledge form to Lisa Craig, MLH Finance, 3803 West Chester Pike, Newtown Square, PA 19073.

As part of this year’s campaign, we would also like to highlight some of the many reasons why our Main Line Health family feels compelled to give to the United Way. Whether the United Way has helped you or someone you know, or you’ve volunteered for an agency that receives funding from the United Way, we want to hear your story. Please upload your personal stories, photos and reasons to give to the “United Way 2020” channel on MLH To Go or email them to

Thank you for your invaluable support as we demonstrate the power of Main Line Health in changing the lives of those who are most in need in our communities near and far.

With deep appreciation,

Jack Lynch, FACHE                               John Schwarz

President and CEO                                      Vice President of Administration

Main Line Health                                         Lankenau Medical Center

Posted in Uncategorized | Leave a comment

Wellspring: A New Intranet Experience at MLH


I am excited to announce that today we launched a new intranet platform at Main Line Health called Wellspring. Wellspring will serve as a central hub for internal communication as well as a knowledge management and resource portal by providing MLH users with information on, and access to, applications, policies, benefits, updates, and other information.

It also provides enhanced collaboration as we engage across the System and work in an integrated fashion to achieve a STEEEP experience across MLH.

Providing our employees and medical staff with an intranet that has a significantly improved user experience and functionality– as well as governance to ensure the content remains relevant and up-to-date– is one of the many ways that we will advance digital innovation at MLH in 2020.

I invite you to watch the brief video below for a tour of Wellspring and then take a moment to open your Internet Explorer browser and experience it for yourself!

In the Quick Links section on the homepage, you’ll find a link to this video as well as a list of FAQs to help you become familiar with Wellspring.

As with everything we do, we needed teamwork and collaboration to bring this project to life. Thank you to those who played a role in contributing to Wellspring whether through participating in focus groups, building out content or providing input through the pilot phase.

With appreciation,


Posted in Uncategorized | Leave a comment

New intranet coming to MLH on January 28

Main Line Health is launching a new intranet on January 28 called Wellspring. Wellspring is built within the Office 365 environment allowing some users (dependent on type of Office 365 license) to access other Office applications and collaboration tools.

Wellspring will serve as a central hub for internal communication as well as knowledge management and resource portal by providing MLH users with information on and access to applications, policies, benefits, updates, and other information. We hope Wellspring serves as a valuable resource as you continue to make Main Line Health the best place to give and receive compassionate, human care.

View the attached preview of Wellspring and instructions on how to use it.

Wellspring tutorial

Posted in Uncategorized | Leave a comment

LIMR researcher to receive Lifetime Achievement Award from the American College of Cardiology

By Donna Loyle, communications specialist, LIMR

Charles Antzelevitch, PhD, professor and executive director of cardiovascular research at the Lankenau Institute for Medical Research (LIMR), will receive the 2020 Lifetime Achievement Award from the American College of Cardiology (ACC) for his groundbreaking research into abnormal heart rhythms.

“We are so proud that Dr. Antzelevitch has been named for this very prestigious award from his colleagues in the cardiovascular field,” said George Prendergast, PhD, president and CEO of LIMR. “For many years, Dr. Antzelevitch has played a pivotal role in global advancements of important investigations that have the potential to significantly improve cardiac care today and in the future.”

Dr. Antzelevitch, who also serves as director of research for Lankenau Heart Institute, studies arrhythmia syndromes via electrophysiology. He has devoted much of his career to the study of atrial fibrillation and inherited cardiac arrhythmias (e.g., Long QT, Short QT and J Wave Syndromes), the latter of which can contribute to sudden cardiac death of young adults and infants.

Dr. Antzelevitch and fellow LIMR researcher Gan-Xin Yan, MD, PhD, convened a consensus conference in 2015 to update the scientific and clinical communities on the mechanisms, diagnosis, prognosis, risk stratification, and treatment of J Wave Syndromes. In 2016, the report of the J-Wave Expert Consensus Conference was published simultaneously in three biomedical journals, a highly unusual occurrence that speaks to the importance of their work.

Dr. Antzelevitch and his research colleagues also have contributed significantly to studies aimed at the development of new treatments for atrial fibrillation. And he and his lab team are engaged in organ bioengineering studies, including cloning hearts that one day could be used in heart transplants.

“I am honored and humbled by this recognition from the ACC and am grateful to the awards committee and board of trustees,” said Dr. Antzelevitch, who is a fellow of the ACC and was the recipient of the Society’s Distinguished Scientist Award in 2011. “I share this honor with the members of my lab team past and present who have contributed immensely to the advancement of science and to the many breakthroughs in cardiovascular research that have benefitted patients at Main Line Health and throughout the world.”

During his 42-year career, Dr. Antzelevitch’s contributions to the scientific literature include more than 550 original papers and reviews, over 380 abstracts and seven books. His research has been funded by public agencies such as the National Institutes of Health, the State of New York Department of Health, and the State of New York Stem Cell Center; organizations such as the American Heart Association and Heart Rhythm Society; private foundations such as the W.W. Smith Charitable Trust, and Martha and Wistar Morris Fund; as well as many pharmaceutical, biotechnology and device companies.

Dr. Antzelevitch’s award will be presented at a gala ceremony during ACC’s 69th Annual Scientific Session in Chicago in March.

For more on Dr. Antzelevitch’s research, visit

Posted in Uncategorized | Leave a comment

LIMR seminar on colitis, colon cancer

All clinicians and researchers are welcome to the one-hour seminar “IDO1 in colitis and colon cancer: mechanisms, phenotypes and opportunities.”

Thursday, January 30, 2020, at 2 p.m. in McLean Conference Room, Lankenau Medical Center.

In recent years, researchers, including those at LIMR, have determined that the enzyme IDO1 drives about half of all human cancers by shielding the growing tumor from the body’s immune attackers.

The session’s speaker will be Matthew Ciorba, MD, associate professor of medicine and director of the Inflammatory Bowel Disease Center and IBD research at Washington University School of Medicine, St. Louis. He is nationally recognized for his clinical expertise in managing complex cases of Crohn’s disease and ulcerative colitis, as well as advancing novel research directed at improving patient care. Dr. Ciorba’s basic-translational research program examines how probiotic microbiota and tryptophan metabolism impact intestinal inflammation and GI health.

Posted in Uncategorized | Leave a comment

Clear and Consistent Documentation in the Physical Exam

In evaluating clinical documentation since EPIC launch, we have noticed the prolific use of note templates, especially for documenting physical exams.  This is a problem because we often see that the physical exam documented in an H and P or progress note does not match the HPI, subjective and assessment and plan for that patient.  For instance, patients noted to have acute respiratory failure may have the first line of their physical exam state “in no acute distress” when they may actually be in respiratory distress.  Or a clear lung exam may be noted, when that is not the case.  A patient with severe malnutrition may have a physical exam that starts with “well-developed and well-nourished.”  This conflicting information is causing us to be subject to audits by the insurance companies, who then refuse to reimburse us for these diagnoses that are not clearly and consistently documented throughout the medical record.   So when you are closing out a note, please take a moment to tweak your templates and proof-read, to be sure you are presenting a clear and consistent picture of your patient.

Posted in Uncategorized | Leave a comment

Reminder Regarding MLHPP After Visit Summary Verbiage Changes

Dear MLHPP Physicians and Office Leadership,

As you know, MLHPP promotes the health of our shared patient community by facilitating a focus on value based care delivery.  Our success requires us to demonstrate our commitment to high quality, reduced cost and evolution of our practice models to ensure continual improvement.  The MLHPP Managing Committee knows that MLHPP specialty providers are committed to supporting this work.  Ensuring PCP follow up is another important part of achieving our goals, as evidence shows that having a PCP involved with patients’ care is associated with higher quality and lower costs.  Hence, we are interested in ensuring that patients understand the importance of seeing a PCP.

As Chair of the MLHPP Network Development Committee, I am writing to request that each MLHPP specialty care practice revise the After Visit Summary in their EMR to recommend that patients see their primary care provider (PCP) regularly.  Additionally, it will provide information about how MLH can help them find a PCP if the patient does not have one.  These changes were recommended by the MLHPP Managing Committee.  The suggested language is pasted in below as well as contained in the attached document.  We are supportive if you choose to modify the language to better align with your practice.

We are requesting that the after visit summaries of all MLHPP practices be revised to include this language by Friday, November 1, 2019.  Please do not hesitate to let me know if you have any questions, concerns or feedback.

Suggested Verbiage:

{Specialty Practice Name} strongly recommends that you visit a Primary Care Provider (PCP) regularly. Your PCP can help you implement the recommendations we gave you today, coordinate care among your specialists, as well as make sure you are up to date with wellness exams, immunizations and preventive screenings.  Your PCP can also help when you are feeling sick, potentially avoiding the need for urgent care or emergency department visits.  For these reasons, it is important that you follow up with your PCP at least annually or more often based upon your medical conditions.  If you do not have a PCP, please call 1-866-CALL-MLH (1-866-225-5654) or go to Find a Doctor for help with finding one.

To view the summary verbiage changes, click here.


Lawrence L. Livornese Jr. MD FACP, FIDSA

Posted in Uncategorized | Leave a comment

RFID Go-Live for Main Line Health Begins January 13, 2020

After many months of planning Main Line Heath will begin using Stryker Surgi-Count Radio Frequency Identification (RFID) in the Operating Rooms, Labor and Delivery, and C-Section Rooms commencing January 13, 2020. This technology will take our sponge tracking process to a higher level of safety as all sponges used during a case must be scanned in and out to ensure no sponge is left behind.

The timeline and staff education are outlined in the table below.

Bryn Mawr Go-Live: Jan 13th Lankenau Go-Live: January 15th
Morning In-Service:   December 17th Morning In-Service:   December 6th
Hands-on training: January 3, 6, 8, 9 Hands-on training: January 6, 8, 9, 14
Paoli Go-Live: Jan 20th Riddle Go-Live: January 22nd
Morning In-Service:   January 8th Morning In-Service:   December 11th
Hands-on training: January 9, 14, 15, 17 Hands-on training: January 16, 17, 20, 21

Staff education via in servicing has begun and hands on training will begin January 3rd as outlined above. In addition, clinical resources from Stryker will be on site in all areas impacted throughout go-live and for follow-up support post go-live.

One key workflow change is that all sponges need to be removed from the surgical field and counted into SurgiCount prior to patients leaving the room. This means all sponges must come off of the field versus being thrown away in drapes that may occur in some instances at this time.

We ask your support and patience and we transition to this new technology to improve patient safety.


Patrick Ross, Jr., MD PhD – Chair, Department of Surgery

Joseph M. Gobern, MD, MBA, FACOG – Chair, Department of Obstetrics & Gynecology

Sean M. Rowland, CRNA, MS, MBA – Surgical Services Director, Health System

Posted in Uncategorized | Leave a comment

Clinical Trial of the Week: For patients with Barrett’s esophagus who have undergone radiofrequency ablation

By Donna Loyle, communications specialist, LIMR

Researchers at Main Line Health are conducting a prospective, randomized clinical trial to determine if orally administered vitamin A (retinoic acid, dosages: 5,000 – 10,000 IU) can induce modification of the esophageal lining in patients who have undergone radiofrequency ablation of their Barrett’s tissue. The modification of the new esophageal lining may be less leaky to refluxed acid.

Eligible patients are randomized into one of two study arms. One group receives treatment with orally administered vitamin A. The other group receives a placebo.

The principal investigators for study #F/N-R20-3895L are Bob Etemad, MD, and James Mullin, PhD. For more information, call Dr. Mullin at 484-476-2703, email: or visit

Posted in Uncategorized | Leave a comment